These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 23948143)

  • 1. Toward the practical implementation of eye-related bioavailability prediction models.
    Pepić I; Lovrić J; Cetina-Čižmek B; Reichl S; Filipović-Grčić J
    Drug Discov Today; 2014 Jan; 19(1):31-44. PubMed ID: 23948143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments in ocular drug delivery.
    Chen H
    J Drug Target; 2015; 23(7-8):597-604. PubMed ID: 26453157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Models and Approaches Describing the Metabolism, Transport, and Toxicity of Drugs Administered by the Ocular Route.
    Dumouchel JL; Chemuturi N; Milton MN; Camenisch G; Chastain J; Walles M; Sasseville V; Gunduz M; Iyer GR; Argikar UA
    Drug Metab Dispos; 2018 Nov; 46(11):1670-1683. PubMed ID: 30111625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase partition: its use in the prediction of membrane permeation and drug action in the eye.
    Lien EJ; Alhaider AA; Lee VH
    J Parenter Sci Technol; 1982; 36(2):86-93. PubMed ID: 7077469
    [No Abstract]   [Full Text] [Related]  

  • 6. Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model.
    Paixão P; Gouveia LF; Morais JA
    Int J Pharm; 2012 Jun; 429(1-2):84-98. PubMed ID: 22449410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro cell culture models to study the corneal drug absorption.
    Reichl S; Kölln C; Hahne M; Verstraelen J
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):559-78. PubMed ID: 21381983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Industrial perspective in ocular drug delivery.
    Ali Y; Lehmussaari K
    Adv Drug Deliv Rev; 2006 Nov; 58(11):1258-68. PubMed ID: 17079049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Subconjunctival administration of drugs].
    Nuritdinov VA
    Vestn Oftalmol; 1979; (4):44-7. PubMed ID: 505722
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug delivery to the posterior segment of the eye.
    Thrimawithana TR; Young S; Bunt CR; Green C; Alany RG
    Drug Discov Today; 2011 Mar; 16(5-6):270-7. PubMed ID: 21167306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments of in silico predictions of oral bioavailability.
    Zhu J; Wang J; Yu H; Li Y; Hou T
    Comb Chem High Throughput Screen; 2011 Jun; 14(5):362-74. PubMed ID: 21470180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corneal cell culture models: a tool to study corneal drug absorption.
    Dey S
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):529-32. PubMed ID: 21500964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-based in vitro models for predicting drug permeability.
    Sarmento B; Andrade F; da Silva SB; Rodrigues F; das Neves J; Ferreira D
    Expert Opin Drug Metab Toxicol; 2012 May; 8(5):607-21. PubMed ID: 22424145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral bioavailability and first-pass effects.
    Kwan KC
    Drug Metab Dispos; 1997 Dec; 25(12):1329-36. PubMed ID: 9394021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A New Vision for the Eye: Unmet Ocular Drug Delivery Needs.
    Rivers HM; Ray Chaudhuri S; Shah JC; Mittal S
    Pharm Res; 2015 Sep; 32(9):2814-23. PubMed ID: 26055402
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives.
    Buckley ST; Fischer SM; Fricker G; Brandl M
    Eur J Pharm Sci; 2012 Feb; 45(3):235-50. PubMed ID: 22178532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADME evaluation in drug discovery. 9. Prediction of oral bioavailability in humans based on molecular properties and structural fingerprints.
    Tian S; Li Y; Wang J; Zhang J; Hou T
    Mol Pharm; 2011 Jun; 8(3):841-51. PubMed ID: 21548635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Animal versus human oral drug bioavailability: do they correlate?
    Musther H; Olivares-Morales A; Hatley OJ; Liu B; Rostami Hodjegan A
    Eur J Pharm Sci; 2014 Jun; 57(100):280-91. PubMed ID: 23988844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution.
    Darwich AS; Pade D; Ammori BJ; Jamei M; Ashcroft DM; Rostami-Hodjegan A
    J Pharm Pharmacol; 2012 Jul; 64(7):1008-24. PubMed ID: 22686346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability and pharmacokinetic analysis of drug responding systems.
    Smolen VF
    Annu Rev Pharmacol Toxicol; 1978; 18():495-522. PubMed ID: 348066
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.